The role of SLC 2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT 1 deficiency syndrome
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: The first mutations identified in SLC 2A1, encoding the glucose transporter type 1 (GLUT 1) protein of the blood–brain barrier, were associated with severe epileptic encephalopathy. Recently, dominant SLC 2A1 mutations were found in rare autosomal dominant families with various forms of epilepsy including early onset absence epilepsy (EOAE), myoclonic astatic epilepsy (MAE), and genetic generalized epilepsy (GGE). Our study aimed to investigate the possible role of SLC 2A1 in various forms of epilepsy including MAE and absence epilepsy with early onset. We also aimed to estimate the frequency of GLUT 1 deficiency syndrome in the Danish population. One hundred twenty patients with MAE, 50 patients with absence epilepsy, and 37 patients with unselected epilepsies, intellectual disability (ID), and/or various movement disorders were screened for mutations in SLC 2A1. Mutations in SLC 2A1 were detected in 5 (10%) of 50 patients with absence epilepsy, and in one (2.7%) of 37 patient with unselected epilepsies, ID, and/or various movement disorders. None of the 120 MAE patients harbored SLC 2A1 mutations. We estimated the frequency of SLC 2A1 mutations in the Danish population to be approximately 1:83,000. Our study confirmed the role of SLC 2A1 mutations in absence epilepsy with early onset. However, our study failed to support the notion that SLC 2A1 aberrations are a cause of MAE without associated features such as movement disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy.
Helbig, I., Mefford, H. C., Sharp, A. J., Guipponi, M., Fichera, M., Franke, A., Muhle, H., de Kovel, C., Baker, C., von Spiczak, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.292 · Cited by 551 · cited 1×
“3 microdeletions are known risk factors for GGE and absence epilepsy.(12,13) Both mother and daughter experienced absence epilepsy and both harbor the SLC2A1 mutation as well as the 15q13.”
BackgroundSelf-citationGlucose Transporter 1 Deficiency as a Treatable Cause of Myoclonic Astatic Epilepsy
Mullen, S. A., Marini, C., Suls, A., Mei, D., Della Giustina, E., Buti, D., Arsov, T., Damiano, J., Lawrence, K., De Jonghe, P., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.102 · Cited by 138
Self-citation
Cited by
Symonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459
Klepper, J., Akman, C., Armeno, M., Auvin, S., Cervenka, M., Cross, H. J., De Giorgis, V., Della Marina, A., Engelstad, K., Heussinger, N., et al. (2020) · Epilepsia Open · doi:10.1002/epi4.12414 · Cited by 285
Vatine, G. D., Al-Ahmad, A., Barriga, B. K., Svendsen, S., Salim, A., Garcia, L., Garcia, V. J., Ho, R., Yucer, N., Qian, T., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.04.002 · Cited by 233
Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
Metadata
- Authors
- Larsen, J., Johannesen, K. M., Ek, J., Tang, S., Marini, C., Blichfeldt, S., Kibæk, M., von Spiczak, S., Weckhuysen, S., Frangu, M., Neubauer, B. A., Uldall, P., Striano, P., Zara, F., MAE working group of the EuroEPINOMICS RES Consortium, Kleiss, R., Simpson, M., Muhle, H., Nikanorova, M., Jepsen, B., Tommerup, N., Stephani, U., Guerrini, R., Duno, M., Hjalgrim, H., Pal, D., Helbig, I., & Møller, R. S.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2015-11-05
- Volume
- 56
- Issue
- 12
- Pages
- e203-8
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2157508298
- Cited by
- 101
- References
- 2
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.